Hakyoung Kim

Hakyoung Kim

Auto-generated profile, based on publicly available information

Hakyoung Kim

Affiliation Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
HKHakyoung Kim
Hakyoung Kim
WPWon Park
Won Park
YKYoung Seok Kim
Young Seok Kim
YKYeon Joo Kim
Yeon Joo Kim
Kim H, et al. J Gynecol Oncol. 2019 Jun;31:e35. https://doi.org/10.3802/jgo.2020.31.e35

16 March 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HKHakyoung Kim
Hakyoung Kim
SLSae Byul Lee
Sae Byul Lee
JKJisun Kim
Jisun Kim
ICIl Yong Chung
Il Yong Chung
HKHee Jeong Kim
Hee Jeong Kim
SASei Hyun Ahn
Sei Hyun Ahn
Purpose: The aim of this study was to evaluate the chronological changes over 14 years in the survival of Korean patients with breast cancer. We also sought to investigate the factors that may have influenced the changes in survival rate. Materials and methods: We retrospectively analyzed 17,776 breast cancer patients who were treated at Asan Medical Center between January 2000 and December 2013. Patient information was collected from the Asan database, including age at diagnosis, clinical manifestation, pathology report, types of treatment and modality, types of recurrence, and follow-up period. We classified the patients into two cohorts according to the year of their surgery (P1: 2000–2007 and P2: 2008–2013) and compared survival and recurrence between both cohorts. Results: We observed that patients treated more recently had better survival outcomes. The 5-year breast cancer-specific survival increased from 94.0% in P1 to 96.6% in P2 (p<0.001), and the 5-year disease-free survival increased from 87.9% in P1 to 91.2% in P2 (p<0.001). When analyzed by type of recurrence, distant metastasis-free survival increased to a significant degree. In subgroup analysis by the subtypes of breast cancer, the survival rates improved in all of the subtypes except triple negative breast cancer, and the improvement was more prominent in subtypes with overexpressed human epidermal growth factor receptor 2. Conclusion: This study showed improvement in breast cancer survival over the succeeding years, which is consistent with the advancement in systemic therapy.

31 December 2018 in Vascular Specialist International
Verified
Journal Article
Open access
HKHakyoung Kim
Hakyoung Kim
YHYoungjin Han
Youngjin Han
GKGi-Young Ko
Gi-Young Ko
MJMin-Jae Jeong
Min-Jae Jeong
KCKyunghak Choi
Kyunghak Choi
TKTae-Won Kwon
Tae-Won Kwon
Surgery is the most common risk factor for pulmonary embolism (PE) in patients with a recent venous thromboembolism (VTE). This study reviewed clinical outcomes of preoperative inferior vena cava filter (IVCF) use in patients with acute VTE during abdominal-pelvic cancer or lower extremity orthopedic surgeries. We retrospectively analyzed 122 patients with a recent VTE who underwent IVCF replacement prior to abdominal-pelvic cancer or lower extremity orthopedic surgery conducted between January 2010 and December 2016. Demographics, clinical characteristics, postoperative IVCF status, risk factors for a captured thrombus, and clinical outcomes were collected for these subjects. Among the 122 study patients who were diagnosed with acute VTE in the prior 3 months and underwent preoperative IVCF replacement, 70 patients (57.4%) received abdominal-pelvic cancer surgery and 52 (42.6%) underwent lower extremity orthopedic surgery. There were no perioperative complications associated with IVCF in the study population and no cases of symptomatic PE postoperatively. A captured thrombus in the filter was identified postoperatively in 16 patients (13.1%). Logistic regression analysis indicated that postoperative anticoagulation within 48 hours significantly reduced the risk of a captured thrombus (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.08-0.94; P=0.032). A captured thrombus in preoperative IVCF was identified postoperatively in 16 patients (13.1%). Postoperative anticoagulation within 48 hours reduces the risk of captured thrombus in these cases.

1 January 2022 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
BKBong Kyun Kim
Bong Kyun Kim
SASung Gwe Ahn
Sung Gwe Ahn
SOSe Jeong Oh
Se Jeong Oh
HKHakyoung Kim
Hakyoung Kim
EKEunyoung Kang
Eunyoung Kang
KSKorean Breast Cancer Society
Korean Breast Cancer Society
Kim BK, et al. J Breast Cancer. 2021 Dec;25:e2. https://doi.org/10.4048/jbc.2022.25.e2